Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial

Francesco Nuzzo 1, Alessandro Morabito 1, Adriano Gravina 1, Francesca Di Rella 1, Gabriella Landi 1, Carmen Pacilio 1, Vincenzo Labonia 1, Emanuela Rossi 1, Ermelinda De Maio 1, Maria Carmela Piccirillo 1, Giuseppe D’Aiuto 1, Renato Thomas 1, Massimo Rinaldo 1, Gerardo Botti 1, Maurizio Di Bonito 1, Massimo Di Maio 1, Ciro Gallo 2, Francesco Perrone 1*, Andrea de Matteis 1

Abstract

Background: To evaluate whether weekly schedules of docetaxel-based chemotherapy were superior to 3-weekly ones in terms of quality of life in locally advanced or metastatic breast cancer.

Methods: Patients with locally advanced or metastatic breast cancer, aged ≤ 70 years, performance status 0-2, chemotherapy-naive for metastatic disease, were eligible. They were randomized to weekly or 3-weekly combination of docetaxel and epirubicin, if they were not treated with adjuvant anthracyclines, or docetaxel and capecitabine, if treated with adjuvant anthracyclines. Primary end-point was global quality of life change at 6-weeks, measured by EORTC QLQ-C30. With two-sided alpha 0.05 and 80% power for 35% effect size, 130 patients per arm were needed.

Results: From February 2004 to March 2008, 139 patients were randomized, 70 to weekly and 69 to 3-weekly arm; 129 and 89 patients filled baseline and 6-week questionnaires, respectively. Global quality of life was better in the 3-weekly arm (p = 0.03); patients treated with weekly schedules presented a significantly worsening in role functioning and financial scores (p = 0.02 and p < 0.001). Neutropenia and stomatitis were worse in the 3-weekly arm, where two toxic deaths were observed. Overall response rate was 39.1% and 33.3% in 3-weekly and weekly arms; hazard ratio of progression was 1.29 (95% CI: 0.84-1.97) and hazard ratio of death was 1.38 (95% CI: 0.82-2.30) in the weekly arm.

Conclusions: In this trial, the weekly schedules of docetaxel-based chemotherapy appear to be inferior to the 3-weekly one in terms of quality of life in patients with locally advanced or metastatic breast cancer.

Trial registration: ClinicalTrials.gov NCT00540800.

Background

Chemotherapy is a cornerstone of the treatment of advanced breast cancer. Taxanes represent, together with anthracyclines, a class of drugs with very strong evidence of efficacy. Particularly, docetaxel is effective both against locally advanced and metastatic breast
cancer, either as single-agent [1-5] or in combination with other drugs, like anthracyclines [6-9] or capecitabine [10]. However, with such combinations, the most common side effects are myelo-suppression and its complications, neutropenic fever and/or infection. While docetaxel is usually given every 3 weeks, a weekly schedule was proposed to improve the toxicity profile of the drug, particularly neutropenia and febrile neutropenia, without decreasing antitumoral activity [11,12]. In metastatic breast cancer, weekly docetaxel as single agent
was active and well tolerated, also in elderly patients and in those with deteriorated performance status [13,14]; similarly, combinations of weekly docetaxel with epirubicin or capecitabine are also characterized by a favourable toxicity profile and antitumor activity [15,16]. Particularly, weekly docetaxel and capecitabine have demonstrated preclinical antitumor synergy; this synergy is thought to occur from docetaxel-mediated up-regulation of thymidine phosphorylase, an enzyme responsible for the relative tumor selectivity of capecitabine [17]. However, no comparison in terms of quality of life between weekly and 3-weekly schedules of docetaxel-based chemotherapy has been reported to date.

On these bases, we planned a phase III randomized clinical trial to test whether a weekly schedule of docetaxel combined with either weekly epirubicin or capecitabine was superior to standard 3-weekly scheduling in terms of quality of life in patients with locally advanced or metastatic breast cancer.

Methods

Eligibility criteria

Women with locally advanced or metastatic breast cancer, aged ≤ 70 years, not previously treated with chemotherapy for metastatic disease were eligible. Patients were required to have an Eastern Cooperative Oncology Group performance status of 0 to 2, adequate bone marrow, (absolute granulocyte count ≥ 2,000/mm³, platelets ≥ 100,000/mm³, haemoglobin ≥ 10 g/dl), renal (serum creatinine ≤ 1.25 upper normal limit) and liver (total bilirubin ≤ 1.5 times upper normal limit; AST and ALT ≤ 1.25 upper normal limit in absence of liver metastases and ≤ 2.5 times upper normal limit in presence of liver metastases) function. Previous adjuvant or neoadjuvant chemotherapy as well as previous endocrine therapy for metastatic disease was allowed. Radiotherapy was allowed, either adjuvant or for metastatic disease. Patients were excluded if they had a positive history of other types of cancer (except for radically resected carcinoma-in-situ of the cervix or non-melanoma skin cancer), had received docetaxel as adjuvant chemotherapy, had symptomatic brain metastases, or serious medical conditions potentially compromising study participation. Pregnant or lactating women were ineligible. All patients were required to provide written informed consent; the Independent Ethical Committee of the National Cancer Institute of Naples approved the protocol (ClinicalTrials.gov NCT00540800).

Treatment schedules

Patients not previously treated with anthracyclines were randomized to weekly or 3-weekly combination of docetaxel and epirubicin [15,18,19]; treatment schemes chosen for locally advanced breast cancer patients had a higher planned dose-intensity than those chosen for those with metastatic disease. Patients pre-treated with anthracyclines were randomized to weekly or 3-weekly combination of docetaxel plus capecitabine [16,20]. Dose and schedule details are reported in Table 1.

Docetaxel was administered as a 1-hour intravenous infusion. Epirubicin was administered as 10 minutes intravenous infusion, before docetaxel. Capecitabine was administered orally. Treatment delays for a maximum of 3 weeks or dose reduction of chemotherapy of 25% or 50% following hematological or non-hematological toxicity were planned by protocol.

Premedication with orally prednisone, 50 mg in 3-weekly and 25 mg in weekly arm, was performed as follows: at -12, -3 and -1 hours before chemotherapy and at +12, +24 and +36 hours after every administration of chemotherapy. Prophylactic antiemetic treatment with 5-HT3 antagonists was given from the first infusion. Granulocyte colony-stimulating factor (G-CSF) was administered at 5 mcg/kg/day subcutaneously in case of grade 4 neutropenia until neutrophil count >2000/mm³. Prophylactic use of G-CSF was mandated for patients with locally advanced breast cancer treated with 3-weekly docetaxel and epirubicin.

Baseline and treatment evaluations

Staging included history and physical examination, performance status score, routine laboratory studies, ECG, chest radiographs, abdomen ultrasound scan or computed tomography, bone scan, skeletal radiographs (if the bone scan was abnormal). Patients were monitored weekly by complete hematology and before every cycle with complete chemistry analyses, record of toxicity, adverse events, and physical examination. Evaluation of tumor response was performed after 3 and 6 cycles for patients with metastatic disease: patients with major response or stable disease continued treatment up to a maximum of 6 courses. For patients with locally advanced disease evaluation of tumor response was performed after 4 cycles and thereafter surgery was planned, if feasible.

Assessment of quality of life

Two instruments were applied: the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) and the Daily Diary Card. The EORTC QLQ-C30 is a 30-item self-reporting questionnaire [21]. It is composed of 5 multi-item functional subscales: physical, role, emotional, social and cognitive functioning; three multi-item symptom scales measuring fatigue, pain, and emesis; a global health status subscale; and six single items to assess financial impact and symptoms such as dyspnea, sleep disturbance, appetite, diarrhea, and constipation.
Scores were computed according to EORTC instructions [22]. For functioning scales (i.e. those exploring physical, role, emotional, cognitive and social functioning and global health status), the higher the value the better the level of function. For symptoms scales and items, the higher the value the worse the severity of symptoms. Questionnaires were administered before randomization and 6 weeks after beginning of treatment in both arms.

The Daily Diary Card was designed by the Medical Research Council Lung Cancer Working Party [23] to capture rapid and transient changes in health and quality of life, which may occur on a day-to-day basis during cancer treatment. Patients had to score 8 items (sleeping, mood, well-being, level of activity, nausea, vomiting, appetite loss and pain) daily, from day 1 (first day of chemotherapy administration) to day 42 (first 6 weeks of treatment).

**Assessment of objective response and toxicity**
Response evaluation was performed according to response evaluation criteria in solid tumor (RECIST). Patients who stopped treatment because of death, toxicity or refusal before restaging were defined as non-responders in the calculation of response rate.

Toxicity was evaluated according to National Cancer Institute - Common Toxicity Criteria (NCIC-CTC) version 2.0. For each type of toxicity, the worst degree experienced throughout the treatment was computed for each patient.

**Calculation of dose-intensity**
Total delivered dose (mg/m²) was calculated by summing all delivered drug doses. Actual time on treatment was calculated as the difference between the last date of treatment administration and the date of treatment start, considering the last cycle as lasting the planned number of weeks. Dose intensity was calculated dividing total dose by time on treatment and was expressed as mg/m²/week.

**Study design and sample size**
The study was designed as a single centre randomised phase III study with quality of life as primary end-point. Global health status scale of EORTC QLQ-C30 after six weeks from the start of chemotherapy was used to plan sample size.

A sample size of 130 in each group was required to have 80% power to detect an effect size of 0.35 (i.e. a difference between mean scores of global health status equal to 35% of the standard deviation) after six weeks of chemotherapy, using a two group t-test with a 0.050 two-sided significance level (nQuery Advisor® 4.0, Statistical Solutions Ltd, Cork, Ireland). This difference, although small, was considered of potential clinical interest. Considering a small dropout rate, 280 overall patients were planned.

Secondary endpoints included response rate, toxicity and overall survival. Patients were randomly assigned to the two arms of the trial in a 1:1 ratio. Randomization was performed by means of a computer-driven minimization procedure. Stratification factors were: group of treatment (locally advanced vs metastatic not pretreated with anthracyclines vs metastatic previously treated with anthracyclines), performance status (0 vs. 1 vs. 2) and age (≤50, >50 years).

### Table 1 Regimens and drug doses of control and experimental arms

| Setting                                    | Treatment Arm | Regimens     | Dose           | Schedule                  | Reference      |
|--------------------------------------------|---------------|--------------|----------------|---------------------------|----------------|
| Locally advanced                           | Control       | Epirubicin   | 75 mg/m², d 1  | Every 3 weeks for 4 cycles | de Matteis A, 2002 |
|                                            |               | Docetaxel    | 80 mg/m², d 1  |                           |                |
|                                            | Experimental  | Epirubicin   | 30 mg/m², dd 1-8-15 | Every 4 weeks for 3 cycles | Wenzel C, 2002 |
|                                            |               | Docetaxel    | 35 mg/m², dd 1-8-15 |                           |                |
| Metastatic, no previous anthracyclines     | Control       | Epirubicin   | 60 mg/m², d 1  | Every 3 weeks for 6 cycles | Trudeau ME, 1999 |
|                                            |               | Docetaxel    | 75 mg/m², d 1  |                           |                |
|                                            | Experimental  | Epirubicin   | 25 mg/m², dd 1-8-15 | Every 4 weeks for 6 cycles | Wenzel C, 2002 |
|                                            |               | Docetaxel    | 30 mg/m², dd 1-8-15 |                           |                |
| Metastatic, previously treated with anthracyclines | Control       | Capecitabine | 1000 mg/m², b.i.d., dd 1-14 | Every 3 weeks for 6 cycles | Pronk LC, 2000 |
|                                            |               | Docetaxel    | 75 mg/m², d 1  |                           |                |
|                                            | Experimental  | Capecitabine | 625 mg/m², b.i.d., dd 5-18 | Every 4 weeks for 6 cycles | Nadella P, 2002 |
|                                            |               | Docetaxel    | 35 mg/m², dd 1-8-15 |                           |                |
Statistical analysis
Since the study was stopped prematurely, analyses of efficacy were definitely underpowered. For quality of life, the primary end-point of the study, the actual size gives an 80% power to detect an effect size of 48% for the experimental arm with a two-sided significance level of 0.05. At 6 weeks, mean differences from baseline values were calculated for each domain or symptom, within the two treatment groups. Differences from baseline scores were compared between treatments by a multivariable linear regression model, with treatment and baseline values as covariates. For Daily Diary Card, the daily rate of patients falling into the two worst scores was calculated for each item.

For secondary end-points only descriptive analyses were performed. Response rate was defined as the number of complete plus partial responses divided by the total number of patients enrolled in each comparison arm. Median follow-up was calculated according to the inverted Kaplan-Meier technique [24]. Progression-free survival was defined as the interval between the date of randomization and disease progression or death whichever occurred first; patients alive and not progressive were censored at the date of the last follow-up information. Overall survival was defined as the interval from the date of randomization and the date of death or the date of last follow-up information for living patients. For both progression-free and overall survival, median values and hazard ratios (HR) of weekly vs 3-weekly arms were reported.

Data are presented for the whole series of patients and scattered by the three subgroups defined by stage of disease and previous treatment with anthracyclines.

Results
Patient characteristics
From February 2004 to March 2008, 139 patients were enrolled in the study, 70 in the weekly and 69 in the 3-weekly arm. The enrollment was slower than planned and was definitively stopped following the publication of the results of a trial that compared weekly vs 3-weekly schedules of taxanes in adjuvant breast cancer, indicating that in adult patients docetaxel was more effective if given every 3 weeks [25].

Two patients were lost, immediately after randomization, in the weekly and one in the 3-weekly arm, respectively, while one patient was found ineligible after randomization in the weekly arm (Figure 1). Baseline characteristics of the patients are well balanced between the two arms, with the exception of ECOG performance status ≥1 and visceral involvement that were slightly more frequent in the weekly arm (Table 2).

Treatment compliance
Median average relative dose intensity of treatment was similar in the two arms; 75% and 70% of patients received all the planned therapy in the control and experimental arms, respectively. The rate of patients receiving all planned cycles of docetaxel and capecitabine was quite low in both the 3-weekly and weekly arms (47.6% and 40.0%, respectively - see Additional File 1).

Quality of life
Compliance with quality of life assessment was 94% and 70% in the 3-weekly and 97% and 62% in the weekly arm, at baseline and 6 weeks, respectively. There was a statistically significant (p = 0.03) difference in terms of quality of life scores favouring the control arm (Table 3 and additional file 2a). Among the five functional sub-scores of the EORTC QLQ-C30, patients treated with weekly schedules presented a significantly worsening in role functioning (p = 0.02). Among the nine symptom sub-scores of the QLQ-C30 questionnaire (Additional file 2b), no significant differences were found between 3-weekly and weekly arms, except for the financial sub-score that was worse in the weekly than in the control arm (p < 0.001).

Daily Diary Cards were compiled and delivered by 55 and 52 patients in the 3-weekly and by 51 and 46 in the weekly arm, after 3 and 6 weeks, respectively. The rates of patients falling into the two worst categories for each item day by day (Figure 2) show that nausea and vomiting had negligible impact in both arms. Daily profiles were consistent with a negative impact of 3-weekly treatment in the first week and the reverse during subsequent weeks.

Tumor response and overall survival
Both therapeutic regimens showed similar antitumor activity. The response rate was 39.1% (95% exact CI: 27.6-51.6) in the 3-weekly and 33.3% (95% exact CI: 22.2-46.0) in the weekly arm. Seven patients (10%) showed a complete response in the 3-weekly and 2 patients (3%) in the weekly arm.

Median follow-up was 32.9 months in the 3-weekly and 33.0 months in the weekly arm. After 86 (64%) events, the median progression-free survival was 15.2 months in the 3-weekly and 13.1 months in the weekly arm (HR = 1.29; 95% exact CI: 0.84-1.97). With regard to overall survival, 59 events were reported. The median overall survival was 42.9 months in the 3-weekly and 33 months in the weekly arm (HR = 1.38; 95% exact CI: 0.82-2.30). Data on efficacy are summarized in Table 4, where also data scattered by treatment group are reported.

Toxicity
Hematological and non-hematological toxicities are summarized in Table 5. Among hematological toxicities, neutropenia was common and it was more frequent and
Figure 1 The CONSORT flowchart

Table 2 Description of patients by treatment arm and clinical setting

|                      | Whole set | Locally advanced | Metastatic not pre-treated with anthracyclines | Metastatic pre-treated with anthracyclines |
|----------------------|-----------|------------------|----------------------------------------------|--------------------------------------------|
|                      | 3-weekly  | Weekly           | 3-weekly                                     | Weekly                                     | 3-weekly                                     |
|                      | N = 69    | N = 66           | N = 22                                       | N = 20                                     | N = 26                                       |
|                      | N = 20    |                  |                                              |                                            |                                            |
|                      | N = 26    |                  |                                              |                                            |                                            |
|                      | N = 21    |                  |                                              |                                            |                                            |
|                      | N = 1    |                  |                                              |                                            |                                            |
| Age, median (range), yrs |          |                  |                                              |                                            |                                            |
|                      | 52 (33-68) | 50 (30-69) | 48 (33-65) | 45 (30-66) | 54 (34-67) | 53 (38-66) | 52 (36-68) | 54 (31-69) |
| ECOG performance status, n (%) |          |                  |                                              |                                            |                                            |
| 0                    | 60 (87.0) | 49 (74.2) | 21 (95.5) | 19 (95.0) | 21 (80.8) | 16 (61.5) | 18 (85.7) | 14 (70.0) |
| 1                    | 7 (10.1)  | 15 (22.7) | 1 (4.5)  | 1 (5.0)  | 4 (15.4)  | 9 (34.6)  | 2 (9.5)   | 5 (25.0)  |
| 2                    | 2 (2.9)   | 2 (3.1)  | -        | -        | 1 (3.8)  | 1 (3.8)  | 1 (4.8)   | 1 (5.0)   |
| ER or PgR positive, n (%) |          |                  |                                              |                                            |                                            |
|                      | 40 (58.0)| 38 (57.6) | 10 (45.5)| 7 (31.8) | 17 (65.4)| 19 (73.1)| 13 (61.9)| 12 (60.0) |
| Previous epirubicin, n (%) |          |                  |                                              |                                            |                                            |
| neoadjuvant          | -        | -        | -       | -        | -        | -        | 21 (100) | 20 (100)  |
| adjuvant             | -        | -        | -       | -        | -        | -        | 3 (14.3) | 1 (5.0)   |
| both                 |          |          | -       | -        | -        | -        | 18 (85.7)| 17 (85.0) |
| Dose of previous epirubicin, median (range), mg/m² |          |                  |                                              |                                            |                                            |
|                      | -        | -        | -       | -        | -        | -        | 422 (340-600)| 485 (289-779)|
| At least one target lesion, n (%) |          |                  |                                              |                                            |                                            |
|                      | 53 (76.8)| 45 (68.2) | 22 (100) | 17 (77.3)| 20 (76.9)| 17 (65.4)| 11 (52.4)| 11 (55.0)|
| Dominant site of disease, n (%) |          |                  |                                              |                                            |                                            |
| soft tissues (chest wall, breast and nodes) |          |                  |                                              |                                            |                                            |
| bone                 | 31 (44.9)| 22 (33.3) | 22 (100) | 20 (100) | 6 (23.1) | 1 (3.8)  | 3 (14.3) | 1 (5.0) |
|                      | 6 (8.7)  | 4 (6.1)  | -       | -        | 5 (19.2) | 2 (7.7)  | 1 (4.8)  | 2 (10.0) |
| viscera (including pleura) |          |                  |                                              |                                            |                                            |

Nuzzo et al. BMC Cancer 2011, 11:75
http://www.biomedcentral.com/1471-2407/11/75
Table 3 EORTC quality of life scores by treatment arm

|                              | 3-weekly mean (SD) | Weekly mean (SD) | Mean difference (SD) | P value* |
|------------------------------|--------------------|------------------|----------------------|----------|
| Global QoL                   |                    |                  |                      |          |
| N = 48                       | 62.8 (22.8)        | 64.0 (21.2)      | 67.9 (16.0)          | 60.0 (19.0) | 5.0 (26.0) | -3.5 (20.5) | 0.03     |
| Mean baseline score (SD)     | 3-weekly          | Weekly           | 3-weekly             | Weekly       |                      |          |
| Physical functioning         | 86.3 (16.6)        | 81.9 (19.6)      | 82.3 (16.8)          | 78.0 (18.0) | -4.0 (11.8) | -3.9 (14.3) | 0.64     |
| Role functioning             | 84.7 (22.2)        | 79.3 (26.0)      | 84.0 (21.2)          | 72.0 (23.4) | -0.7 (22.3) | -7.3 (24.7) | 0.02     |
| Emotional functioning        | 59.2 (23.5)        | 60.4 (22.2)      | 71.5 (19.1)          | 64.8 (24.4) | 12.3 (21.6) | 4.5 (18.5)  | 0.055    |
| Cognitive functioning        | 88.9 (14.7)        | 89.8 (21.0)      | 90.3 (14.9)          | 83.7 (23.7) | 1.4 (19.1)  | -6.1 (18.5) | 0.055    |
| Social functioning           | 81.6 (21.5)        | 80.5 (25.0)      | 80.2 (26.6)          | 69.5 (28.6) | -1.4 (32.8) | -11.0 (29.7) | 0.07     |
| Symptom                      |                    |                  |                      |          |
| Pain                         | 23.6 (27.9)        | 26.0 (25.3)      | 15.3 (19.1)          | 224 (19.9) | -8.3 (23.8) | -3.7 (19.9) | 0.08     |
| Loss of appetite             | 13.2 (23.6)        | 13.8 (23.5)      | 15.3 (21.7)          | 146 (21.1) | 2.1 (29.5)  | 0.8 (24.1)  | 0.86     |
| Constipation                 | 13.9 (16.6)        | 15.4 (24.8)      | 17.7 (23.9)          | 200 (28.0) | 4.3 (26.6)  | 5.8 (31.9)  | 0.71     |
| Financial                    | 18.8 (26.5)        | 19.5 (30.7)      | 15.3 (23.8)          | 35.0 (33.3) | -3.5 (22.0) | 15.4 (37.3) | 0.0007   |
| Fatigue                      | 19.4 (19.7)        | 24.1 (25.0)      | 31.6 (19.0)          | 369 (20.6) | 12.2 (16.0) | 12.7 (26.1) | 0.39     |
| Nausea/vomiting              | 5.2 (12.0)         | 7.3 (14.5)       | 17.4 (25.0)          | 195 (22.6) | 12.2 (24.0) | 12.2 (21.4) | 0.87     |
| Sleeping disturbance         | 27.7 (28.9)        | 40.0 (31.3)      | 22.9 (26.8)          | 292 (32.2) | -5.7 (28.1) | -10.8 (28.6) | 0.90     |
| Diarrhoea                    | 5.6 (14.3)         | 2.6 (9.0)        | 9.0 (17.9)           | 12.2 (20.8) | 3.5 (19.7)  | 9.4 (20.2)  | 0.31     |
| Dyspnoea                     | 5.6 (12.6)         | 14.6 (25.9)      | 9.0 (16.5)           | 192 (21.2) | 3.5 (15.7)  | 4.2 (25.2)  | 0.10     |

SD: standard deviation; * bold p-values are statistically significant.

Figure 2 Pattern of worst scores reported by the Daily Diary Card during the first 6 weeks of treatment. Gray lines represent weekly schedules of docetaxel; red lines represent 3-weekly schedules of docetaxel.
severe in the 3-weekly arm, where two patients also experienced febrile neutropenia. Conversely, no relevant differences were observed in anaemia and thrombocytopenia between the two arms. Among non-hematological toxicities, stomatitis was worse in the 3-weekly arm, while no striking differences between the two arms were found in other non-hematological toxicities. Two toxic deaths were observed, both in the 3-weekly arm with the combination of docetaxel and epirubicin: one patient, 67 years old, with metastatic disease, suffered of grade 4 anemia, neutropenia, thrombocytopenia and stomatitis after the third cycle of chemotherapy and died for neutropenic infection; the other patient, 50 years old, with locally advanced disease, died for rectal bleeding nine days after the first cycle of chemotherapy. Data of severe toxicity scattered by arm and treatment group are reported in the Additional file 3.

Discussion and Conclusions

This study shows that weekly schedules of docetaxel combined with epirubicin or capecitabine were worse than the standard 3-weekly schedules in terms of global quality of life, role functioning and financial scores, despite the worse hematological toxicity of the latter, as first-line chemotherapy for locally advanced or metastatic breast cancer. Daily quality of life profiles indicate a positive impact of the weekly treatment only in the first week, while it had a negative impact during subsequent weeks. No major differences in antitumor activity were observed with both schedules.

Two randomized trials compared single-agent docetaxel used either every 3 weeks or weekly in patients with metastatic breast cancer [26,27]. Tabernero et al reported no differences in response rate, but less hematological toxicity in the weekly arm, in a study with 83 randomized patients [27]. Rivera et al, in a study with 118 randomized patients, found a higher response rate in the 3-weekly arm (35.6% vs 20.3%), but patients in this arm experienced more toxicity and there was no difference in progression-free and overall survival [26]. However, none of these two studies included a quality of life assessment. In patients with early breast cancer, Sparano et al. recently reported a randomized phase 3 trial comparing weekly versus 3-weekly docetaxel or paclitaxel after doxorubicin plus cyclophosphamide: a higher 5-year disease-free survival rate in the 3-weekly docetaxel arm (81.2% versus 77.6%) was observed [25]. The quality of life of patients with cancer has been identified as a relevant endpoint in research and clinical practice [28]. The present study is, to our knowledge, the first trial comparing weekly with 3-weekly schedules of docetaxel-based chemotherapy with quality of life as
primary endpoint. At 6 weeks, which we chose as the time-point for the primary analysis, there was a slight imbalance in compliance with fewer questionnaires returned in the weekly arm; in principle, this might favour the weekly arm due to a positive selection bias. But, given that our conclusions are in favour of the 3-weekly schedules, we don’t believe that this difference is critical. Obviously, comparing treatments with different schedules introduces difficulties in quality of life assessment. The EORTC questionnaire explores patient’s feelings during the last week; this might partially affect the observed results, because the time chosen for evaluation corresponded to therapy for the weekly and no therapy for the 3-weekly arm. For this reason we added a daily diary card, to describe as more clearly as possible the changes of quality of life during the whole treatment period. The observed results suggest that the choice of a weekly schedule of docetaxel-based chemotherapy does not improve, but even worsens quality of life of patients, although it is associated with a decrease in haematological toxicity. Our interpretation of this result is that the impact of the reduction of haematological side effects of weekly docetaxel regimens is not enough to counterbalance personal, familiar and social disadvantages associated with more frequent admittance to hospital for weekly administration of antineoplastic drugs. We acknowledge, however, that the impact on familiar and social disadvantages might be affected by regional variation of cancer treatment logistic.

There are several potential limitations of our study. First, the study was stopped prematurely and it is underpowered according to initial plan. Early stopping was independent of treatment effects, but was prompted by the slow accrual rate and the publication of the results of the trial by Sparano et al. [25] that made continuation unethical. However, the sample size of our trial is among the largest reported for studies evaluating quality of life in metastatic breast cancer and the study actually has 80% power to detect a 48% improvement in quality of life, that is an effect of medium size, that might be considered as clinically relevant. Second, a questionable issue is that patients at different stages of disease were eligible for the study; different stages, in fact, may imply worse or better QoL levels; however, our plans were based on the consideration that, once

| Table 5 Worst NCI-CTC grade of toxicity by patient, in the whole group of patients |
|--------------------------------------|--------------------------------------|--------------------------------------|
| Grade                               | 3-weekly, n (%)                      | Weekly, n (%)                        |
|                                     | 0    | 1    | 2    | 3    | 4    | 5    | 0    | 1    | 2    | 3    | 4    | 5    |
| Allergy                             | 68 (98,6) | 1 (1,0) | -    | -    | -    | -    | 65 (98,5) | -    | 1 (1,5) | -    | -    | -    |
| Anaemia                             | 48 (69,6) | -    | 13 (18,8) | 7 (10,1) | -    | 1 (1,4) | -    | -    | 49 (74,2) | 8 (12,1) | 7 (10,6) | 2 (3,0) | -    |
| Neutropenia                         | 21 (30,4) | -    | 3 (4,3) | 19 (27,5) | 26 (37,7) | -    | 36 (54,5) | 10 (15,2) | 9 (13,6) | 7 (10,6) | 4 (6,1) | -    |
| Thrombocytopenia                    | 66 (95,7) | -    | 2 (2,9) | -    | 1 (1,4) | -    | 64 (97,0) | 1 (1,5) | -    | 1 (1,5) | -    | -    |
| Febrile Neutropenia                 | 67 (97,1) | 1 (1,4) | 1 (1,4) | -    | -    | 66 (100,0) | -    | -    | -    | -    | -    | -    |
| Neutropenic infection               | 59 (85,5) | 4 (5,8) | 5 (7,2) | -    | -    | 1 (1,4) | 61 (92,4) | 1 (1,5) | 4 (6,1) | -    | -    | -    |
| Bleeding                            | 66 (95,7) | 2 (2,9) | -    | -    | -    | 1 (1,4) | 64 (97,0) | 1 (1,5) | -    | 1 (1,5) | -    | -    |
| Cardiac                             | 61 (88,4) | 6 (8,7) | 1 (1,4) | 1 (1,4) | -    | -    | 59 (89,4) | 4 (6,1) | 2 (3,0) | 1 (1,5) | -    | -    |
| Fatigue                             | 43 (62,3) | 16 (23,2) | 10 (14,5) | -    | -    | -    | 41 (62,1) | 11 (16,7) | 13 (19,7) | 1 (1,5) | -    | -    |
| Fever                               | 60 (87,0) | 4 (5,8) | 5 (7,2) | -    | -    | -    | 62 (93,9) | 2 (3,0) | 1 (1,5) | 1 (1,5) | -    | -    |
| Weight loss                         | 69 (100,0) | -    | -    | -    | -    | -    | 64 (97,0) | 1 (1,5) | 1 (1,5) | -    | -    | -    |
| Hair loss                           | 24 (34,8) | 1 (1,4) | 44 (63,8) | -    | -    | -    | 33 (50,0) | 8 (12,1) | 25 (37,9) | -    | -    | -    |
| Cutaneous                           | 60 (87,0) | 3 (4,3) | 4 (5,8) | 1 (1,4) | 1 (1,4) | -    | 51 (77,3) | 8 (12,1) | 6 (9,1) | 1 (1,5) | -    | -    |
| Conjunctivitis                      | 66 (95,7) | 1 (1,4) | 2 (2,9) | -    | -    | -    | 61 (92,4) | 3 (4,5) | 2 (3,0) | -    | -    | -    |
| Anorexia                            | 67 (97,1) | 2 (2,9) | -    | -    | -    | -    | 66 (100,0) | -    | -    | -    | -    | -    |
| Constipation                        | 63 (91,3) | 4 (5,8) | 2 (2,9) | -    | -    | -    | 63 (95,5) | 2 (3,0) | 1 (1,5) | -    | -    | -    |
| Diarrhoea                           | 53 (76,8) | 9 (13,0) | 6 (8,7) | 1 (1,4) | -    | -    | 56 (84,8) | 6 (9,1) | 4 (6,1) | -    | -    | -    |
| Dysgeusia                           | 67 (97,1) | 2 (2,9) | -    | -    | -    | -    | 63 (95,5) | 3 (4,5) | -    | -    | -    | -    |
| Nausea                              | 26 (37,7) | 25 (36,2) | 17 (24,6) | 1 (1,4) | -    | -    | 31 (47,0) | 26 (39,4) | 8 (12,1) | 1 (1,5) | -    | -    |
| Vomiting                            | 46 (66,7) | 14 (20,3) | 7 (10,1) | 1 (1,4) | 1 (1,4) | -    | 46 (69,7) | 14 (21,2) | 4 (6,1) | 2 (3,0) | -    | -    |
| Stomatitis                          | 39 (56,5) | 18 (26,1) | 8 (11,6) | 2 (2,9) | 2 (2,9) | -    | 44 (66,7) | 17 (25,8) | 4 (6,1) | 4 (6,1) | -    | -    |
| Abdominal pain                      | 58 (84,1) | 5 (7,2) | 3 (4,3) | 3 (4,3) | -    | -    | 60 (90,9) | 4 (6,1) | 2 (3,0) | -    | -    | -    |
| Skeletal pain                       | 64 (92,8) | 1 (1,4) | 4 (5,8) | -    | -    | -    | 66 (100,0) | -    | -    | -    | -    | -    |
| Diabetes                            | 69 (100,0) | -    | -    | -    | -    | -    | 63 (95,5) | 1 (1,5) | 1 (1,5) | 1 (1,5) | -    | -    |
| Hepatic                             | 64 (92,8) | 4 (5,8) | 1 (1,4) | -    | -    | -    | 57 (86,4) | 8 (12,1) | 1 (1,5) | -    | -    | -    |
| Neurologic                          | 62 (89,9) | 6 (8,7) | -    | 1 (1,4) | -    | -    | 59 (89,4) | 5 (7,6) | -    | 1 (1,5) | 1 (1,5) | -    |
| Pulmonary                           | 69 (100,0) | -    | -    | -    | -    | -    | 64 (97,0) | 2 (3,0) | -    | -    | -    | -    |
balance is warranted through randomization and stratification, the comparison should not be biased. Similar considerations can be done for the heterogeneity of chemotherapeutic regimens used at the different stages. Third, the evidence of efficacy of some of the treatments schedules chosen for this trial was quite low; however, this limitation might also be interpreted as a value of the present trial that provides some more evidence on treatment schedules proposed as promising and no longer studied, like the combination of weekly docetaxel and capetitabine [16]. Thanks to randomization, our data suggest that this weekly combination is less promising than expected.

The results of the present study should not be generalized to weekly regimens with other drugs, such as paclitaxel, that has shown a superior efficacy compared to paclitaxel every 3 weeks, both in adjuvant and in metastatic setting, with a different toxicity profile [25,29]. Similarly, the results of this study should not be generalized to different subpopulations of breast cancer patients: weekly docetaxel has proven active and extremely well tolerated among elderly breast cancer patients, a population that would be at risk of toxicity with standard 3-weekly scheduling [30,31]. In conclusion, in our study the weekly schedules of docetaxel-based chemotherapy appeared to be inferior to the 3-weekly ones in terms of quality of life, among adult patients with locally advanced or metastatic breast cancer and should not be preferred for clinical practice.

Additional material

Additional file 1: Table A1. Treatment compliance by treatment arm and clinical setting.

Additional file 2: Figure A1. Mean change in EORTC quality of life scores at 6 weeks from baseline (a = functional scales; b = symptom scales). Gray bars represent weekly schedules of docetaxel; red bars represent 3-weekly schedules of docetaxel.

Additional file 3: Table A2. Grade 3 or worse toxicity (according to NCI-CTC) by treatment arm and clinical setting.

Acknowledgements

The coordinating center is partially supported by “Associazione Italiana per la Ricerca sul Cancro” (AIRC). The Authors thank Jane Bryce, Gianfranco De Feo and Rosa Fiore for assistance in data collection and quality control; Federika Crudele, Gianluca Cranzanella, Fiorella Romano, Manuela Florio, Giovanni de Matteis, Amalia Rocco and Gaetano Bonfanti for data management; Alfonso Savio for informative support and the Campania section of the Lega Italiana per la Lotta contro i Tumori.

Author details

1National Cancer Institute, via M. Semmola, 80131 Napoli, Italy. 2Department of Medicine and Public Health, Second University of Napoli, via L. Armanni, 80138 Napoli, Italy. 3Giuseppe Moscati Hospital, Avellino. 4Azienda USL 6 Livorno.

Authors’ contributions

FN, FP, AdM conceived the study, CG, FP, AdM was involved in study design, FN, AG, FDR, GL, CP, VL, ER, EDL, GDA, RT, MR, GB, MDB carried out the acquisition of data; AM, MCP, MDM performed the quality control of the data; MDM, CG performed the statistical analysis; FN, AM, MCP, FP, AdM were involved in the interpretation of data; FN, AM, MCP, MDM, FP, AdM drafted the manuscript; all authors reviewed and approved the final manuscript.

Competing interests

Honorary: Alessandro Morabito, Roche; Massimo Di Maio, Roche; Francesco Perrone, Roche.

Received: 29 March 2010 Accepted: 16 February 2011

Published: 16 February 2011

References

1. Ravdin PM, Burris HA III, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevoss E, Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracycline-resistant breast cancer. J Clin Oncol 1995, 13:2879-2885.
2. Valero V, Holmes FA, Walters TS, Therault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN: Phase II trial of docetaxel: a new highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995, 13:2868-2894.
3. Nabholz JM, Senn HJ, Bezveda WR, Melinchuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Sedliecek P, Wilking N, Genot JY, Hupperets PSGJ, Pannuti F, Skoflos D, Tomaik EM, Murawsky M, Alakl M, Riva A, Aapro M, 304 Study Group: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999, 17:1413-1424, 304 Study Group.
4. Sjostrøm J, Blomqvist C, Moursenis H, Pluzanska E, Ottoisson-Lonn S, Bengtsson NO, Ostestad B, Mjåland I, Palm-Sjöval M, West E, Valverde V, Anderson H, Bergh J: Docetaxel compared with sequential metotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracyline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999, 35:1194-1200.
5. Chan S, Friedichs K, Noel D, Pintet T, Van Belle S, Vorobiof D, Duarte R, Gil GI, M, Rodroggi L, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzi F, Gonzalez Mancia H, Richardson G, Walpole E, Enomoto N, Murawsky M, Alakl M, Riva A, Crown J, The 303 Study Group: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999, 17:2341-2354.
6. Nabholz JM, Falkson C, Campos D, Santon J, Martin M, Chan S, Pierkowski T, Zaluzki J, Pintet T, Krzakowski M, Vorobiof D, Leonard R, Kennedy J, Adl N, Murawsky M, Riva A, Poullart P, TAX 306 Study Group: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003, 21:968-975.
7. Bontenbal M, Creegers GJ, Braun HJ, de Boer AC, Janssen JT, Leys R, Ruit JB, Goey SH, van der Velden FC, Kerkhof LS, Schouten KL, Schmitz PI, Bokma HJ, Verweij J, Seynaeve C, Dutch Community Setting Trial for the Clinical Trial Group: Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch community setting trial for the clinical trial group of the comprehensive cancer Centre. J Clin Oncol 2005, 23:7081-7088.
8. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N: The effect on tumor response of adding sequential preoperative docetaxel to neoadjuvant doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003, 21:4165-4174.
9. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-Siek AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ofgren RN: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002, 20:1456-1466.
10. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Aoyub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Tweedes C, Van Hazel G, Verma S,
Leonard R. Superior survival with capcitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20:2812-2823.

11. Hainsworth JD, Burris HA, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998, 16:2164-2168.

12. Tomlak E, Piccart MJ, Kerger J, Lips S, Awada A, de Valeriola D, Ravoet C, Lossignol D, Sculler JP, Azanet V. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1994, 12:1458-1467.

13. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000, 18:1212-1219.

14. Hainsworth JD, Burris HA, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, Sullivan T, Baker M, Erland JB, Greco FA. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001, 19:3500-3505.

15. Winzel C, Locker GJ, Pluschnig U, Zielinski CC, Radas M, Oberhuber G, Gnant MF, Taucher S, Jakesz R, Steger GG. Phase I/I trial of weekly epirubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer. Cancer Chemother Pharmacol 2002, 50:155-159.

16. Nadella P, Shapiro C, Otterson A, Hauger M, Edal S, Kraut E, Clinton S, Shah M, Stanek M, Monk P, Villalona-Calero MA. Pharmacologically based scheduling of capcitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 2002, 20:2616-2623.

17. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capcitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998, 4:1013-1019.

18. de Mattiis A, Nuzzo F, D’Aulto G, Labonia V, Landi G, Rossi E, Mastro AA, Botti G, De Maio E, Perrone F. Docetaxel plus epirubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast. A single-center phase II study. Cancer 2002, 94:895-901.

19. Trudeau ME, Crump M, Latreille J, Pritchard KI, Palmer M, Tu D, Shepherd L, Shear N, Shapiro I, Oldfield S, et al: Escalating Doses of Docetaxel and Epirubicin as First Line Therapy for Metastatic Breast Cancer. A Phase I/I Study of the National Cancer Institute of Canada—Clinical Trials Group. Proc Am Soc Clin Oncol 1999, 19, abstr 483.

20. Pronk L, Vasey PA, Sparreboom A, Reignier B, Planting AS, Gordon RJ, Osterwalder B, Verweij J, Twelves C. A phase I and pharmacokinetic study of the combination of capcitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 2000, 83:22-29.

21. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Muller K, Pipes K, Sjogren D, Zee B. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.

22. Fayers P, Aaronson NK, Bjordal K, Cull A, Groenveld M. EORTC QLQ-C30 Scoring Manual. Edited by EORTC. Brussels Belgium, 2. 1999:1-77.

23. Fayers PM, Bleehe NM, Greling DJ, Stephens RJ. Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party. Br J Cancer 1991, 64:299-306.

24. Schermer M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996, 17:543-346.

25. Sparano JA, Wang M, Martin S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358:1663-1671.

26. Diendorf M, Pajak TF, Bubendorf L, Huggins C, Sause W, Fisher B, Trier E, Winer EP, Slevin ML, Berry DA. Phase III trial comparing the use of doxorubicin on an every-3-weeks versus weekly schedule in the treatment of metastatic breast cancer. J Clin Oncol 2008, 26:1642-1649.

27. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Antón A, Laurent C, Mayordomo JI, Estourn N, Lasa I, Guillem V, Garcia-Conde J, Tisara J, Baselga J. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004, 15:1358-1362.

28. Iconomidou G, Mega V, Koutiras A, Iconomidou AV, Kalofonos HP. Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy. Cancer 2004, 101:404-411.

29. Seidman AD, Berry D, Cimiricence C, Harris L, Mus H, Marcom PK, Girson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Morton N, Winer E, Hudes C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008, 26:1642-1649.

30. Hainsworth JD, Burris HA III, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, Sullivan T, Baker M, Erland JB, Greco FA. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer research network phase II trial. J Clin Oncol 2001, 19:3500-3505.

31. Nuzzo F, Morabito A, De Maio E, Di Rella F, Gravina A, Labonia V, Landi G, Pacilio C, Piccirillo MC, Rossi E, D’Aulto G, Thomas R, Gori S, Colozza M, De Plaudo S, Laura R, Signorile G, Gallo C, Perrone F, de Mattiis A. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Crit Rev Oncol Hematol 2008, 66:171-180.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/11/75/prepub

Submit your next manuscript to BioMed Central and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

doi:10.1186/1471-2407-11-75
Cite this article as: Nuzzo et al.: Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial. BMC Cancer 2011 11:75.